Tango Therapeutics, Inc. (TNGX) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Tango Therapeutics, Inc. (TNGX) Earnings Overview
As of June 22, 2026, Tango Therapeutics, Inc. (TNGX) reported trailing twelve-month net income of -$107M, reflecting +26.9% year-over-year growth. The company earned $-0.75 per diluted share over the past four quarters, with a net profit margin of -162.9%.
Looking at the long-term picture, TNGX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$14M in fiscal 2019.
Tango Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RVMD (-$1.37B net income), KYMR (-$315M net income, -794.4% margin), PRAX (-$327M net income), TNGX has comparable earnings metrics. Compare TNGX vs RVMD →
TNGX Earnings vs Peers
Earnings metrics vs comparable public companies
TNGX Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$102M | +22.0% | -$111M | $-0.87 | -162.9% | -178.4% |
| 2024 | -$130M | -28.1% | -$146M | $-1.19 | -309.7% | -346.1% |
| 2023 | -$102M | +5.9% | -$114M | $-1.08 | -278.5% | -312.6% |
| 2022 | -$108M | -85.8% | -$111M | $-1.23 | -435.1% | -446.8% |
| 2021 | -$58M | -12.1% | -$58M | $-0.94 | -157.2% | -157.1% |
| 2020 | -$52M | -268.7% | -$52M | $-1.62 | -678.8% | -681.8% |
| 2019 | -$14M | - | -$15M | $-1.57 | -57.2% | -61.5% |
Download Data
Export TNGX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TNGX — Frequently Asked Questions
Quick answers to the most common questions about buying TNGX stock.
What is TNGX earnings per share (EPS)?
TNGX trailing twelve-month (TTM) diluted EPS is $-0.75, reflecting +26.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Tango Therapeutics, Inc.'s net income?
Tango Therapeutics, Inc. (TNGX) trailing twelve-month net income is $-107M as of 2025. Earnings grew +26.9% year-over-year.
Is TNGX profitable?
TNGX is not currently profitable on a TTM basis, reporting a net loss of $-107M. Net margin is -162.9%. Investors should monitor for a return to profitability.
What is TNGX's earnings growth rate?
TNGX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are TNGX's profit margins?
Tango Therapeutics, Inc. net profit margin is -162.9%, operating margin is -178.4%, and gross margin is +96.3%. Below-average margins reflect competitive or cost pressures. Return on Equity is -37.2%.
Is TNGX growing earnings?
Yes, TNGX earnings are accelerating — EPS growth of +26.9% exceeds the 5-year CAGR of N/A. TTM net income reached $-107M. Earnings momentum is strengthening.
What was TNGX's best earnings year?
Tango Therapeutics, Inc.'s highest annual net income on record is $-14M, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were TNGX's earnings last quarter?
TNGX's most recent reported quarter was Q1 2026. Net income was $-46M with diluted EPS of $-0.32. For a full breakdown of all quarters, see the quarterly earnings table on this page.